CCORE-Galt Fellowship

The College of Pharmacy has established its first industry fellowship with Atlanta-based Galt Pharmaceuticals. The one-year fellowship is for a pharmacy graduate interested in a career in the pharmaceutical industry. 

Fellows will divide their time between the College and Galt, where they will help advance the clinical development of secondary indications of approved drugs and support scientific affairs of Galt products as they move from development to commercialization. Faculty of the College’s Center for Clinical Outcomes Research and Education, or CCORE, will train fellows to conduct research in drug therapy outcomes and help guide their research projects. Fellows will be expected to publish their research results in peer-reviewed publications and to present at scientific conferences, in addition to teaching Mercer students pursuing a Doctor of Pharmacy (Pharm.D.) degree. 

This fellowship will give a graduate in-depth experience in evaluating the economic and clinical outcomes of a drug therapy. New pharmacists and pharmaceutical scientists will have valuable expertise as they transition into the workforce.

Fellows will work alongside Galt co-founder Barry Patel, Pharm.D. (Class of '92). Dr. Patel co-founded his own pharmaceutical outcomes research and education company, Total Therapeutic Management (TTM), along with another Mercer graduate in 1995, and successfully sold the company to Indegene Lifesystems in 2013. His latest venture, Galt Pharmaceuticals, is co-founded with fellow Mercer graduate, William Smith, Pharm.D. (Class of '88), to further develop approved drugs for unmet health care needs, while commercializing them for current needs through a unique distribution model that relies exclusively on independent pharmacies.

Applications from candidates with a Pharm.D. degree or a graduate degree in outcomes research are sought for the July 2018 - June 2019 cycle. Candidates should send their curriculum vitae and a cover letter by Feb. 9, 2018, to Dr. Peasah at Qualified candidates will be contacted for interviews in March.